RxDoctor Payments Data

Erin Frank, PA

Medical · Hartford, CTNPI 1396129458

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,288 of the $14,782 with a category attached, or 83.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,782in general payments, 2019–2025

Across 527 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$1K
  • Merck$930
  • AstraZeneca$616
  • Incyte Corporation$566
  • Pfizer$535
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,28883%
  • Education$3793%
  • Other$2,11514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis63$3,074
Johnson & Johnson(2 entities)44$1,069
Merck37$930
AstraZeneca(2 entities)26$616
Incyte Corporation14$566
Pfizer24$535
Daiichi Sankyo Inc.17$464
Seagen Inc.15$440
Regeneron Healthcare Solutions, Inc.14$401
Genentech USA, Inc.16$389
Eisai Inc.17$376
AbbVie15$354
Pharmacosmos Therapeutics Inc.10$281
Amgen12$265
Astellas Pharma US Inc12$259
E.r. Squibb & Sons, L.L.C.8$252
Takeda Pharmaceuticals U.S.A., Inc.8$250
Pharmacyclics LLC, An Abbvie Company11$233
Beigene USA, Inc.8$231
Bayer8$210
Array Biopharma Inc9$202
Sanofi7$199
Lilly USA, LLC8$190
Stemline Therapeutics Inc.6$165
Exelixis Inc.8$155
Gilead(2 entities)7$154
Puma Biotechnology, Inc.8$150
AVEO Pharmaceuticals, Inc.3$139
Pharmaessentia USA Corporation4$125
Sobi, Inc6$124
Bristol Myers Squibb5$113
Rigel Pharmaceuticals, Inc.4$111
ADC Therapeutics America, Inc.5$108
Global Blood Therapeutics, Inc.1$107
Mirati Therapeutics, Inc.4$104
Ipsen Biopharmaceuticals, Inc4$103
GSK4$99
Morphosys, US Inc.4$89
Taiho Oncology, Inc.4$88
Kyowa Kirin, Inc.4$87
Tersera Therapeutics LLC3$82
Boehringer Ingelheim3$76
Beone Medicines USA, Inc.3$76
EUSA Pharma (US) LLC3$64
EMD Serono, Inc.3$61
Heron Therapeutics, Inc.2$54
Spectrum Pharmaceuticals Inc.2$46
Caris MPI, Inc.2$46
Deciphera Pharmaceuticals Inc.2$35
Alnylam Pharmaceuticals Inc.2$35
Blue Earth Diagnostics1$35
Genmab U.S., Inc.1$32
Agios Pharmaceuticals, Inc.1$30
Syndax Pharmaceuticals, Inc.1$30
Adaptive Biotechnologies Corporation1$25
G1 Therapeutics, Inc.1$24
Myovant Sciences Inc.1$24
Biocon Biologics Inc1$23
Legend Biotech USA Inc.1$23
Accord Healthcare, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,782 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$3,745
Medicare patients
23
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$52,200
XareltoRivaroxaban24$13,831
Enoxaparin Sodium22$6,336
Anastrozole40$629
Letrozole17$553
Prochlorperazine Maleate42$482
Lidocaine-PrilocaineLidocaine/Prilocaine41$439
Dexamethasone37$419
Acyclovir17$218
Duloxetine Hcl13$165
Warfarin Sodium29$117
Prednisone41$110
Gabapentin11$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$535$52,20072 claims
Johnson & JohnsonXarelto$1,069$13,83124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.

Other medical in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →